Evidence map›Paper›PMID 29087507›Full record

ArticleRheumatology (Oxford, England)2018

The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countries.

Sarah Hewlett, John Kirwan, Christina Bode, Fiona Cramp, Loreto Carmona, Emma Dures, Matthias Englbrecht, Jaap Fransen, Rosemary Greenwood, Sofia Hagel and 7 more

Registry-linked trialOpen access · bronzeAbstract readEvaluation StudyValidation Study
In one paragraph

Article in Rheumatology (Oxford, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05502731 (Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05502731 phase4unknown statusnot on this mapstarted 2022, after this paper: background citation

Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis

TypeinterventionalSponsorLeiden University Medical CenterRan2022 to 2025Enrolled40ConditionsRheumatoid ArthritisArmsFilgotinib, Adalimumab
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Psychometric properties and cross-language equivalence of the revised Bristol Rheumatoid Arthritis Fatigue and the Rheumatoid Arthritis Impact of Disease scales in rheumatoid arthritis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 6 countries.

Sarah HewlettNursing & Midwifery, University of the West of England, Bristol, UK.
John KirwanMusculoskeletal Research, Bristol University, Bristol, UK.
Christina BodeDepartment of Psychology, Health and Technology, University of Twente, Twente, The Netherlands, Madrid, Spain.
Fiona CrampNursing & Midwifery, University of the West of England, Bristol, UK.
Loreto CarmonaInstituto de Salud Musculoesquelética, Madrid, Spain.
Emma DuresNursing & Midwifery, University of the West of England, Bristol, UK.
Matthias EnglbrechtDepartment of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Jaap FransenRheumatology Department, Radboud University, Nijmegen, The Netherlands.
Rosemary GreenwoodDepartment of Research and Innovation, Bristol Royal Infirmary, Bristol, UK.
Sofia HagelOrthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Maart van de LaarDepartment of Psychology, Health and Technology, University of Twente, Twente, The Netherlands, Madrid, Spain.
Anna MoltoRheumatology Department, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France.
Joanna NicklinDepartment of Research and Innovation, Bristol Royal Infirmary, Bristol, UK.
Ingemar F PeterssonOrthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Marta RedondoDepartment of Psychology, Universidad Camilo José Cela, Madrid, Spain.
Georg SchettDepartment of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Laure GossecRheumatology Department, Sorbonne Universites, UPMC Univ Paris 06, Hôpital Pitié Salpêtrière, AP-HP, Paris, France.
University of the West of England · GBBristol Royal Infirmary · GBFriedrich-Alexander-Universität Erlangen-Nürnberg · DELund University · SEUniversity of Twente · NLCamilo José Cela University · ESDélégation Paris 5 · FRInstituto de Salud Musculoesquelética · ESRadboud University Nijmegen · NLUniversité Paris Cité · FRUniversity of Bristol · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To evaluate the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ), the revised Bristol Rheumatoid Arthritis Numerical Rating Scales (BRAF-NRS V2) and the Rheumatoid Arthritis Impact of Disease (RAID) scale in six countries. Methods: We surveyed RA patients in France, Germany, The Netherlands, Spain, Sweden and the UK, including the HAQ, 36-item Short Form Health Survey (SF-36) and potential revisions of the BRAF-NRS coping and Spanish RAID coping items. Factor structure and internal consistency were examined by factor analysis and Cronbach's α and construct validity by Spearman's correlation. Results: A total of 1276 patients participated (76% female, 25% with a disease duration <5 years, median HAQ 1.0). The original BRAF-MDQ four-factor structure and RAID single-factor structure were confirmed in every country with ⩾66% of variation in items explained by each factor and all item factor loadings of 0.71-0.98. Internal consistency for the BRAF-MDQ total and subscales was a Cronbach's α of 0.75-0.96 and for RAID, 0.93-0.96. Fatigue construct validity was shown for the BRAF-MDQ and BRAF-NRS severity and effect scales, correlated internally with SF-36 vitality and with RAID fatigue (r = 0.63-0.93). Broader construct validity for the BRAFs and RAID was shown by correlation with each other, HAQ and SF-36 domains (r = 0.46-0.82), with similar patterns in individual countries. The revised BRAF-NRS V2 Coping item had stronger validity than the original in all analyses. The revised Spanish RAID coping item performed as well as the original. Conclusion: Across six European countries, the BRAF-MDQ identifies the same four aspects of fatigue, and along with the RAID, shows strong factor structure and internal consistency and moderate-good construct validity. The revised BRAF-NRS V2 shows improved construct validity and replaces the original.

Indexed as

Cost of IllnessHealth SurveysSeverity of Illness IndexAdultArthritis, RheumatoidCross-Sectional StudiesFactor Analysis, StatisticalFatigueFemaleFranceGermanyHumansMaleMiddle AgedNetherlandsPsychometricsculturalfatigueimpactPROMsrheumatoid arthritisvalidation

Identifiers

PMID29087507
PMCPMC5850460
OpenAlexW2766796109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.